NADAC acquisition cost data for NITROFURANTOIN MONO-MCR 100 MG. This is a generic medication, typically more affordable than brand-name equivalents.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 00185012201 | $0.4111 | 2022-12-21 | Rx |
| 00185012210 | $0.4111 | 2022-12-21 | Rx |
| 00480347001 | $0.4111 | 2022-12-21 | Rx |
| 00591365801 | $0.4111 | 2022-12-21 | Rx |
| 13811071910 | $0.4111 | 2022-12-21 | Rx |
| 16714043901 | $0.4111 | 2022-12-21 | Rx |
| 47781030301 | $0.4111 | 2022-12-21 | Rx |
| 50268062511 | $0.4111 | 2022-12-21 | Rx |
| 50268062515 | $0.4111 | 2022-12-21 | Rx |
| 60687063301 | $0.4111 | 2022-12-21 | Rx |
Generic: Nitrofurantoin | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $5.2M | 3,180 | 1,675 | $5.31 |
| 2020 | $7.3M | 3,131 | 1,452 | $7.51 |
| 2021 | $7.8M | 3,115 | 1,521 | $7.89 |
| 2022 | $7.3M | 2,902 | 1,375 | $8.33 |
| 2023 | $8.1M | 3,155 | 1,444 | $8.38 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| Florida | $2.4M | 70,723 | 42,506 |
| Texas | $2.3M | 57,491 | 29,794 |
| California | $1.6M | 40,747 | 20,867 |
| New York | $1.4M | 38,151 | 19,749 |
| North Carolina | $930.9K | 24,251 | 10,805 |
| Tennessee | $901.4K | 24,493 | 11,210 |
| Ohio | $869.7K | 23,668 | 10,112 |
| Alabama | $818.1K | 20,353 | 8,565 |
| Pennsylvania | $810.8K | 25,964 | 11,969 |
| Michigan | $762.4K | 17,168 | 8,768 |
| California | $750.0K | 279 | 176 |
| Georgia | $686.2K | 19,624 | 9,002 |
| New York | $650.2K | 229 | 109 |
| Illinois | $645.9K | 17,622 | 8,338 |
| Indiana | $645.6K | 16,040 | 7,096 |
| Louisiana | $575.8K | 17,863 | 7,057 |
| Texas | $574.9K | 221 | 105 |
| Virginia | $545.8K | 13,674 | 6,517 |
| New Jersey | $529.0K | 14,959 | 8,262 |
| Arizona | $500.7K | 11,763 | 6,126 |
| Ohio | $482.5K | 188 | 76 |
| Kentucky | $481.0K | 12,313 | 5,182 |
| Missouri | $472.4K | 12,441 | 5,526 |
| South Carolina | $470.8K | 12,456 | 5,745 |
| Wisconsin | $426.9K | 9,854 | 3,262 |
| Massachusetts | $390.7K | 12,597 | 5,505 |
| Oklahoma | $387.5K | 9,083 | 3,771 |
| Washington | $384.8K | 8,477 | 3,497 |
| New Jersey | $365.2K | 142 | 56 |
| Pennsylvania | $364.9K | 132 | 55 |
| Iowa | $357.0K | 8,690 | 3,052 |
| Mississippi | $353.2K | 9,797 | 4,291 |
| Maryland | $347.7K | 9,117 | 4,867 |
| Michigan | $337.2K | 144 | 77 |
| Arkansas | $329.1K | 8,506 | 3,606 |
| Florida | $318.5K | 121 | 65 |
| Connecticut | $304.7K | 7,932 | 3,537 |
| Colorado | $298.8K | 6,690 | 3,209 |
| Washington | $296.9K | 119 | 40 |
| North Carolina | $296.3K | 101 | 45 |
| Oregon | $286.6K | 6,767 | 2,789 |
| Illinois | $278.3K | 101 | 62 |
| Tennessee | $253.1K | 110 | 25 |
| Puerto Rico | $240.1K | 9,094 | 6,889 |
| Minnesota | $221.3K | 4,717 | 1,969 |
| Kansas | $218.2K | 5,932 | 2,343 |
| West Virginia | $217.1K | 5,989 | 2,268 |
| Minnesota | $214.1K | 66 | 19 |
| Maryland | $192.8K | 90 | 35 |
| Nebraska | $192.8K | 4,839 | 1,803 |
| Utah | $191.0K | 4,350 | 2,047 |
| South Carolina | $188.7K | 47 | 26 |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.
Explore More Data Tools
For adjacent public-data tools, methodology notes, and network updates, visit DataPeek Facts.